CELL INTELLIGENCE · 肿瘤细胞治疗研究

前列腺癌中基于 PSMA 的治疗的序贯与联合应用的新兴证据

Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.

人源化 PSMA 靶向 CAR-T 细胞的工程化改造用于强效且特异性清除前列腺癌细胞

Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells.

晚期前列腺癌中的肿瘤细胞表面靶向

Targeting the tumour cell surface in advanced prostate cancer.

前列腺特异性膜抗原作为实体瘤血管导向治疗策略的靶点

Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors.

利用基于 VHH 的 PSMA-Vδ2 双特异性 T 细胞衔接器调动 Vγ9Vδ2 T 细胞对抗前列腺癌

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.

CB307：一种用于治疗 PSMA 阳性肿瘤的双靶向共刺激 Humabody VH 疗法

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.

CB307 是一种首创的免疫治疗药物，能够触发强效的 PSMA 依赖性 T 细胞激活，从而减轻针对无限制 CD137 激动作用的毒理学担忧。

抗 PSMA ScFvD2B 作为诊疗工具的有效性：一篇以叙述为重点的综述

Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review.